Saturday, July 11, 2026

Drug profile · INN

monotherapy

monotherapy is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 5
Pipeline programs 35
News articles 0
Drug details — monotherapy
Class
Route
Patents
5
Programs
35
Data quality
0.70

Quick answer

monotherapy is an FDA-listed pharmaceutical active ingredient.

Key facts

INN monotherapy

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. Capecitabine monotherapy Phase 3 · First People's Hospital · Gastric Cancer
  2. Start antiplatelet monotherapy Phase 3 · Chinese Academy of · Intracerebral Hemorrhage
  3. UC-IMM-2101 Phase 3 · Ningbo Cancer Hospital · Only patients with oncologic locally advanced or metastatic
  4. WN43194 Phase 3 · HOFFMANN-LA ROCHE · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Dise
  5. 2023/3668 Phase 2 · George Institute for · Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-lo
  6. D798MC00002 Phase 2 · AstraZeneca · Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig
  7. Genomically Directed Monotherapy Phase 2 · Vera Therapeutics · Malignant Neoplasm of Breast
  8. INCB 00928-104 Phase 2 · Incyte · Anaemia associated with myelofibrosis

Related patents

  1. US 12178875

    Lymphatic system-directing lipid prodrugs

    Expires 2044-12-26T00:00:00.000Z

    granted
  2. US 10993956

    GLA monotherapy for use in cancer treatment

    Expires 2041-04-29T00:00:00.000Z

    granted
  3. US 10342815

    GLA monotherapy for use in cancer treatment

    Expires 2039-07-04T00:00:00.000Z

    granted
  4. US 8962593

    GLA monotherapy for use in cancer treatment

    Expires 2035-02-19T00:00:00.000Z

    granted
  5. US 8957047

    GLA monotherapy for use in cancer treatment

    Expires 2035-02-12T00:00:00.000Z

    granted

Frequently asked questions

What is monotherapy?

monotherapy is an FDA-listed pharmaceutical active ingredient.